Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz; Linda M Henricks; Steven M Offer; Julia Barbarino; Jan H M Schellens; Jesse J Swen; Teri E Klein; Howard L McLeod; Kelly E Caudle; Robert B Diasio; Matthias Schwab

doi:10.1002/cpt.911

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.

Authors

Ursula Amstutz¹, Linda M Henricks², Steven M Offer³, Julia Barbarino⁴, Jan H M Schellens^{2

5}, Jesse J Swen⁶, Teri E Klein⁴, Howard L McLeod⁷, Kelly E Caudle⁸, Robert B Diasio^{3

9}, Matthias Schwab^{10

11

12}

Affiliations

¹ University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
² Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
³ Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
⁵ Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
⁶ Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
⁷ DeBartolo Family Personalized Medicine Institute and the Department of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
⁸ Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
⁹ Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota, USA.
¹⁰ Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
¹¹ Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany.
¹² Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany.

PMID: 29152729
PMCID: PMC5760397
DOI: 10.1002/cpt.911

Abstract

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC^® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

Publication types

Practice Guideline
Systematic Review

MeSH terms

Antimetabolites, Antineoplastic / administration & dosage*
Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / pharmacokinetics
Capecitabine / administration & dosage*
Capecitabine / adverse effects
Capecitabine / pharmacokinetics
Clinical Decision-Making
Dihydrouracil Dehydrogenase (NADP) / genetics*
Dihydrouracil Dehydrogenase (NADP) / metabolism
Drug Dosage Calculations
Fluorouracil / administration & dosage*
Fluorouracil / adverse effects
Fluorouracil / pharmacokinetics
Genotype
Humans
Patient Selection
Pharmacogenetics / standards*
Pharmacogenomic Testing / standards*
Pharmacogenomic Variants*
Phenotype
Precision Medicine / standards*
Predictive Value of Tests

Substances

Antimetabolites, Antineoplastic
Capecitabine
Dihydrouracil Dehydrogenase (NADP)
Fluorouracil

Abstract

Publication types

MeSH terms

Substances

Grants and funding